Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma.
Individual predictive clinical, immunological, or molecular features for definition of patients with lymph-node-positive melanoma who do not benefit from adjuvant postsurgery high-dose interferon alpha treatment are lacking. Expression analysis of classic and non-classic HLA molecules on melanoma cells metastatic to the locoregional lymph node may help select these patients before treatment.
Wagner
S N
SN
Rebmann
V
V
Willers
C P
CP
Grosse-Wilde
H
H
Goos
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic; D006680:HLA Antigens / Q000032:analysis* / Q000187:drug effects / Q000235:genetics; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary / Q000601:surgery; D010641:Phenotype; D011994:Recombinant Proteins; D012189:Retrospective Studies; D015996:Survival Rate; D015854:Up-Regulation
D000970:Antineoplastic Agents; D006680:HLA Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins